Overview
Myeloid/lymphoid neoplasm with JAK2 rearrangement is a rare hematologic malignancy characterized by the PCM1-JAK2 fusion gene, often presenting as myeloproliferative neoplasms (MPN), acute leukemias, or T-cell cutaneous lymphoma 1.Diagnosis
Initial diagnosis often includes myeloproliferative neoplasm (MPN), acute myeloid leukemia (AML), acute lymphocytic leukemia, or T-cell cutaneous lymphoma 1.
Identification of PCM1-JAK2 fusion gene through molecular genetic testing is crucial 1.
Bone marrow biopsy and flow cytometry may support diagnosis by revealing atypical cell populations 1.Management
First-line treatment: Hematologic stem cell transplantation (HSCT) is recommended, particularly for younger patients and those with aggressive disease 1.
Adjunctive therapy: JAK2 inhibitors, such as ruxolitinib, are suggested but efficacy data are limited due to small patient numbers 1.
Supportive care: Includes management of cytopenias, infections, and symptomatic relief 1.Special Populations
Elderly patients: Limited data; HSCT may be less feasible due to comorbidities, focusing more on supportive care and possibly targeted therapies 1.
Comorbidities: Presence of comorbidities may influence treatment decisions, favoring less intensive regimens like targeted therapy over HSCT 1.Key Recommendations
Perform molecular genetic testing to identify PCM1-JAK2 fusion gene for definitive diagnosis (Evidence: Moderate 1).
Consider hematologic stem cell transplantation (HSCT) for younger patients with aggressive disease (Evidence: Moderate 1).
Evaluate JAK2 inhibitors, such as ruxolitinib, for treatment, though efficacy remains to be fully established due to limited data (Evidence: Weak 1).References
1 Kaplan HG, Jin R, Bifulco CB, Scanlan JM, Corwin DR. PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature. The oncologist 2022. link